BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18260957)

  • 1. [Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease].
    Soboleva GN; Pogorelova OA; Kuznetsova TV; Masenko VP; Fomicheva OA; Chernova NA; Rogoza AN; Balakhonova TV; Karpov IuA
    Kardiologiia; 2007; 47(11):9-13. PubMed ID: 18260957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
    Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
    Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
    Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
    Hussein O; Shneider J; Rosenblat M; Aviram M
    J Cardiovasc Pharmacol; 2002 Jul; 40(1):28-34. PubMed ID: 12072574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
    Lunder M; Janić M; Jug B; Sabovič M
    Eur J Intern Med; 2012 Apr; 23(3):261-6. PubMed ID: 22385885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
    Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients.
    Savić V; Eržen B; Janić M; Lunder M; Boncelj M; Kanc K; Janež A; Šabović M
    Diab Vasc Dis Res; 2013 Sep; 10(5):420-5. PubMed ID: 23811602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
    Li Z; Iwai M; Wu L; Liu HW; Chen R; Jinno T; Suzuki J; Tsuda M; Gao XY; Okumura M; Cui TX; Horiuchi M
    Hypertension; 2004 Nov; 44(5):758-63. PubMed ID: 15452025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.
    Boncelj Svetek M; Eržen B; Kanc K; Šabovič M
    J Diabetes Complications; 2017 Mar; 31(3):544-550. PubMed ID: 28012835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus.
    Lunder M; Janić M; Savić V; Janež A; Kanc K; Šabovič M
    Diabetes Res Clin Pract; 2017 May; 127():181-186. PubMed ID: 28384560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
    Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M
    Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
    Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction.
    Westphal S; Abletshauser C; Luley C
    Coron Artery Dis; 2009 Jan; 20(1):81-5. PubMed ID: 19060628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Qi WW; Liu T; Xu G; Li LF; Liang YZ; Ye L; Li GP
    Trials; 2015 Aug; 16():336. PubMed ID: 26248619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
    Ozeki A; Amiya E; Watanabe M; Hosoya Y; Takata M; Watanabe A; Kawarasaki S; Nakao T; Watanabe S; Omori K; Yamada N; Tahara Y; Hirata Y; Nagai R
    J Clin Hypertens (Greenwich); 2014 Aug; 16(8):591-8. PubMed ID: 25039889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
    Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
    Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels.
    Schneider MP; Schmidt BM; John S; Schmieder RE
    J Hypertens; 2011 Sep; 29(9):1757-64. PubMed ID: 21799442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males.
    Janić M; Lunder M; Prezelj M; Šabovič M
    J Cardiopulm Rehabil Prev; 2014; 34(3):208-12. PubMed ID: 24263076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
    Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.